A Retrospective Study on the Efficacy and Safety of Idarubicin Combined with High-Dose Cytarabine Consolidation in Patients with Acute Myeloid Leukemia over 60 Years of Age in First Remission.
10.19746/j.cnki.issn.1009-2137.2023.03.009
- Author:
Jin CAO
1
;
Yao-Zhen YE
1
;
Xiao-Yun ZHENG
1
;
Yi CHEN
1
;
Lu-Ting LUO
1
;
Jing ZHENG
1
;
Ting YANG
1
;
Jian-Da HU
2
Author Information
1. Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.
2. Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.E-mail: drjiandahu@163.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
efficacy;
elderly patients;
post-remission therapy;
safety
- MeSH:
Aged;
Male;
Female;
Humans;
Middle Aged;
Idarubicin/therapeutic use*;
Retrospective Studies;
Cytarabine;
Antineoplastic Combined Chemotherapy Protocols;
Leukemia, Myeloid, Acute/etiology*;
Remission Induction
- From:
Journal of Experimental Hematology
2023;31(3):671-676
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy and safety of idarubicin combined with high-dose cytarabine as a post-remission therapy for elderly patients with acute myeloid leukemia (AML).
METHODS:From November 2017 to June 2021, 24 AML patients aged ≥60 years who were in complete remission for the first time were enrolled in consolidation chemotherapy with idarubicin (10 mg/m2 intravenously once for day 1) combined with high-dose cytarabine (1.5 g/m2 intravenously over 3 hours every 12 hours for day 1-3), and the efficacy and safety were observed.
RESULTS:Among the 24 patients, there were 12 males and 12 females, the median age was 65 (60-78) years old, and the median follow-up time was 23.3 (2-42.7) months. By the end of the follow-up, 15 patients relapsed and 11 patients died. The median disease-free survival (DFS) was 9 months and there were 3 cases of 2-year DFS. The median overall survival (OS) was 16.2 months, and there were 4 cases of 2-year OS. In terms of safety, 6 patients had grade 1-2 non-hematological adverse reactions, 12 patients had grade 3-4 hematological adverse reactions, and a total of 6 patients developed infection after consolidation chemotherapy. Multivariate analysis showed that two induction cycles and high-risk cytogenetic abnormalities were the adverse factors of DFS and OS in elderly patients with AML in this study.
CONCLUSION:For AML patients ≥60 years old in first complete remission, idarubicin combined with high-dose cytarabine as post-remission therapy has a better safety, but compared with other regimens does not improve the prognosis of elderly patients, which needs further exploration.
